1. Home
  2. EDSA vs AIFU Comparison

EDSA vs AIFU Comparison

Compare EDSA & AIFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDSA
  • AIFU
  • Stock Information
  • Founded
  • EDSA 2015
  • AIFU 1998
  • Country
  • EDSA Canada
  • AIFU China
  • Employees
  • EDSA 16
  • AIFU N/A
  • Industry
  • EDSA Biotechnology: Pharmaceutical Preparations
  • AIFU
  • Sector
  • EDSA Health Care
  • AIFU
  • Exchange
  • EDSA Nasdaq
  • AIFU NYSE
  • Market Cap
  • EDSA 14.7M
  • AIFU 12.2M
  • IPO Year
  • EDSA N/A
  • AIFU 2007
  • Fundamental
  • Price
  • EDSA $2.39
  • AIFU $7.29
  • Analyst Decision
  • EDSA Strong Buy
  • AIFU
  • Analyst Count
  • EDSA 2
  • AIFU 0
  • Target Price
  • EDSA $13.00
  • AIFU N/A
  • AVG Volume (30 Days)
  • EDSA 30.7K
  • AIFU 184.4K
  • Earning Date
  • EDSA 08-08-2025
  • AIFU 07-25-2025
  • Dividend Yield
  • EDSA N/A
  • AIFU N/A
  • EPS Growth
  • EDSA N/A
  • AIFU 61.54
  • EPS
  • EDSA N/A
  • AIFU 23.02
  • Revenue
  • EDSA N/A
  • AIFU $247,815,758.00
  • Revenue This Year
  • EDSA N/A
  • AIFU N/A
  • Revenue Next Year
  • EDSA N/A
  • AIFU N/A
  • P/E Ratio
  • EDSA N/A
  • AIFU $0.32
  • Revenue Growth
  • EDSA N/A
  • AIFU N/A
  • 52 Week Low
  • EDSA $1.55
  • AIFU $1.50
  • 52 Week High
  • EDSA $5.59
  • AIFU $7.77
  • Technical
  • Relative Strength Index (RSI)
  • EDSA 73.15
  • AIFU N/A
  • Support Level
  • EDSA $1.89
  • AIFU N/A
  • Resistance Level
  • EDSA $2.23
  • AIFU N/A
  • Average True Range (ATR)
  • EDSA 0.11
  • AIFU 0.00
  • MACD
  • EDSA 0.04
  • AIFU 0.00
  • Stochastic Oscillator
  • EDSA 81.54
  • AIFU 0.00

About EDSA Edesa Biotech Inc.

Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.

About AIFU FANHUA INC SPON ADS EACH REPR 20 ORD SHS

AIFU Inc is an independent financial services provider in China. It offer end-to-end business solutions spanning compliance, technology, products, services, capital flow and professional training. It connects customers with insurance protection, retirement planning, health management, asset management, and family governance services. The company operated in two segments: the insurance agency segment, which derives maximum revenue, consists of providing agency services for distributing life insurance products and non-life insurance products on behalf of insurance companies, and the claims adjusting segment consisting of providing pre-underwriting survey services, claims adjusting services, disposal of residual value services, loading/unloading supervision services and consulting services.

Share on Social Networks: